Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
Joaquim Barreto,
Beatriz Luchiari,
Vaneza L. W. Wolf,
Isabella Bonilha,
Ticiane G. Bovi,
Barbara S. Assato,
Ikaro Breder,
Sheila T. Kimura-Medorima,
Daniel B. Munhoz,
Thiago Quinaglia,
Otavio R. Coelho-Filho,
Luiz Sergio F. Carvalho,
Wilson Nadruz,
Andrei C. Sposito
Affiliations
Joaquim Barreto
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Beatriz Luchiari
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Vaneza L. W. Wolf
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Isabella Bonilha
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Ticiane G. Bovi
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Barbara S. Assato
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Ikaro Breder
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Sheila T. Kimura-Medorima
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Daniel B. Munhoz
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Thiago Quinaglia
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Otavio R. Coelho-Filho
Division of Cardiology, Department of Internal Medicine, Unicamp, Sao Paulo 13083-970, Brazil
Luiz Sergio F. Carvalho
Clarity Healthcare Intelligence, Jundiaí 13214-658, Brazil
Wilson Nadruz
Division of Cardiology, Department of Internal Medicine, Unicamp, Sao Paulo 13083-970, Brazil
Andrei C. Sposito
Atherosclerosis and Vascular Biology Laboratory (Aterolab), Division of Cardiology, State University of Campinas (Unicamp), Sao Paulo 13083-894, Brazil
Stricter control of risk factors has been pursued as a compelling strategy to mitigate cardiovascular events (CVE) in type 2 diabetes (T2D) individuals. However, the achievement rate of the recommended goals has remained low in clinical practice. This study investigated the 2019 ESC guideline recommendation attainment among T2D individuals enrolled in a national cohort held in Brazil. Data from 1030 individuals (mean age: 58 years old; 54% male; mean T2D duration: 9.7 years) were analyzed. The control rates were 30.6% for SBP, 18.8% for LDL-C, and 41% for A1c, and only 3.2% of the study participants met all three targets. Statins and high-intensity lipid-lowering therapy prescription rates were 45% and 8.2%, respectively. Longer T2D duration and those at higher CV risk were less likely to be controlled. Longer diabetes duration and higher CV risk were inversely related to the chance of achieving the recommended targets. Treatment escalation using conventional therapies would be sufficient to gain optimal control in most of the study sample. In conclusion, a minimal proportion of T2D individuals comply with guidelines-oriented CV prevention targets. Given the significant burden of the disease, and the substantial effect size predicted for these therapies, bridging this gap between guidelines and clinical practice should be considered an urgent call to public health managers.